Mechanism of action
Naproxen reversibly inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes in a non-selective manner. This inhibition prevents the conversion of arachidonic acid to prostaglandin H2, the precursor of prostanoids including prostaglandins, prostacyclin, and thromboxanes.
COX-1 inhibition leads to decreased production of prostaglandins that protect the gastric mucosa, maintain renal perfusion, and support platelet function. This accounts for naproxen's gastrointestinal and renal adverse effects, as well as its antiplatelet activity.
COX-2 inhibition reduces the synthesis of prostaglandins involved in inflammation, pain, and fever. COX-2 is upregulated at sites of inflammation and in response to inflammatory mediators. By blocking COX-2, naproxen provides its therapeutic anti-inflammatory, analgesic, and antipyretic effects.
The result is reduced inflammation, pain relief, fever reduction, and inhibition of platelet aggregation. Unlike aspirin, naproxen's inhibition of COX enzymes is reversible and competitive.
- Naproxen non-selectively inhibits COX-1 and COX-2, reducing prostaglandin synthesis for anti-inflammatory, analgesic, and antipyretic effects
- Half-life of 12-17 hours allows twice-daily dosing, longer than ibuprofen (2-4 hours)
- Black box warnings: cardiovascular thrombotic events (MI, stroke) and GI bleeding/ulceration/perforation
- Contraindicated in third trimester pregnancy (premature ductus arteriosus closure) and perioperative CABG surgery
- Increases bleeding risk when combined with anticoagulants, antiplatelets, or SSRIs; avoid concurrent NSAID use
- Reduces efficacy of ACE inhibitors, ARBs, and diuretics; increases nephrotoxicity risk in volume depletion
- Can precipitate acute kidney injury by inhibiting prostaglandin-mediated renal blood flow, especially in volume-depleted states
- May have lowest cardiovascular risk among non-selective NSAIDs due to sustained antiplatelet effect
Indications
Naproxen is indicated for a variety of inflammatory and pain conditions:
- Osteoarthritis and rheumatoid arthritis: reduces joint pain and inflammation
- Ankylosing spondylitis: manages axial inflammation and pain
- Acute gout: effective for acute gouty arthritis flares
- Primary dysmenorrhea: reduces menstrual pain by inhibiting uterine prostaglandin synthesis
- Tendinitis and bursitis: treats localized musculoskeletal inflammation
- Mild to moderate pain: headaches, dental pain, postoperative pain
- Fever: antipyretic effect through central prostaglandin inhibition
- Juvenile idiopathic arthritis: pediatric inflammatory arthritis
Naproxen sodium formulations have faster absorption and may be preferred for acute pain management. The drug is available over-the-counter at lower strengths and by prescription at higher strengths.
Pharmacokinetics
Absorption: Naproxen is well absorbed from the gastrointestinal tract with bioavailability exceeding 95%. Peak plasma concentrations occur 2-4 hours after oral administration. Naproxen sodium is absorbed more rapidly than naproxen base. Food may delay absorption but does not significantly reduce bioavailability.
Distribution: Naproxen is highly protein-bound (greater than 99%), primarily to albumin. The volume of distribution is approximately 0.16 L/kg. It crosses the placenta and is present in low concentrations in breast milk.
Metabolism: Naproxen undergoes hepatic metabolism primarily via the cytochrome P450 system (CYP2C9 and CYP1A2) to 6-O-desmethylnaproxen, an inactive metabolite. It also undergoes conjugation to form glucuronide metabolites.
Elimination: Naproxen is eliminated primarily by the kidneys, with 95% excreted in urine as metabolites and unchanged drug. The elimination half-life is approximately 12-17 hours, significantly longer than ibuprofen (2-4 hours), which allows for twice-daily dosing. Steady-state concentrations are achieved in 4-5 days with regular dosing.
Special populations: Renal impairment reduces clearance and increases half-life. Elderly patients may have reduced clearance. Hepatic impairment may reduce metabolism.
Adverse effects
Naproxen shares the adverse effect profile common to non-selective NSAIDs, primarily related to COX-1 inhibition:
Gastrointestinal
- Dyspepsia, nausea, abdominal pain: most common adverse effects
- Peptic ulcer disease: gastric and duodenal ulcers due to reduced mucosal prostaglandin protection
- GI bleeding and perforation: serious complications, especially in elderly or with prolonged use
- Diarrhea or constipation
Cardiovascular
- Increased risk of myocardial infarction and stroke: all NSAIDs carry cardiovascular thrombotic risk through COX-2 inhibition reducing prostacyclin while COX-1-mediated thromboxane production continues in platelets (though naproxen may have lower cardiovascular risk than other NSAIDs)
- Hypertension: prostaglandin inhibition affects renal sodium handling and vascular tone
- Fluid retention and edema: can exacerbate heart failure
Renal
- Acute kidney injury: prostaglandin inhibition reduces renal blood flow, especially in volume-depleted states
- Interstitial nephritis: immune-mediated renal inflammation
- Hyperkalemia: reduced aldosterone secretion
- Sodium and water retention
Hematologic
- Antiplatelet effect: reversible inhibition of platelet aggregation, increased bleeding risk
- Anemia: from chronic GI blood loss or bone marrow suppression
Hepatic
- Elevated liver enzymes: transaminitis in 1-15% of patients
- Hepatotoxicity: rare but serious, can progress to liver failure
Hypersensitivity
- Aspirin-exacerbated respiratory disease (AERD): bronchospasm in aspirin-sensitive asthmatics
- Anaphylaxis: rare IgE-mediated or non-IgE reactions
- Skin reactions: rash, Stevens-Johnson syndrome, toxic epidermal necrolysis (rare)
Central nervous system
- Headache, dizziness, drowsiness
- Aseptic meningitis: rare, more common in SLE patients
Other
- Tinnitus and hearing disturbances: at high doses
- Photosensitivity
Contraindications and warnings
Absolute contraindications:
- History of hypersensitivity to naproxen, aspirin, or other NSAIDs
- Active peptic ulcer disease or GI bleeding
- Perioperative pain in CABG surgery: increased cardiovascular thrombotic risk
- Third trimester of pregnancy: risk of premature closure of ductus arteriosus and oligohydramnios
- Aspirin triad (asthma, nasal polyps, aspirin sensitivity): high risk of bronchospasm
Black box warnings:
- Cardiovascular thrombotic events: increased risk of serious cardiovascular thrombotic events, MI, and stroke, which can be fatal; risk may increase with duration of use and in patients with cardiovascular disease or risk factors
- Gastrointestinal bleeding, ulceration, and perforation: serious GI adverse events including bleeding, ulceration, and perforation can occur at any time and without warning; elderly patients and those with prior GI disease are at greater risk
Warnings and precautions:
- Cardiovascular disease: use with caution; naproxen may have lower cardiovascular risk compared to other NSAIDs but still carries risk
- Hypertension: can worsen blood pressure control
- Heart failure: fluid retention can precipitate or worsen heart failure
- Renal impairment: use cautiously; avoid in severe renal failure (CrCl <30 mL/min)
- Hepatic impairment: monitor liver function; use with caution in cirrhosis
- Elderly patients: increased risk of serious GI and cardiovascular adverse events
- Pregnancy: avoid in late pregnancy; use in early pregnancy only if benefit outweighs risk
- Breastfeeding: present in low concentrations in breast milk; generally considered compatible
- Asthma: may precipitate bronchospasm in aspirin-sensitive patients
- SLE and mixed connective tissue disease: increased risk of aseptic meningitis
- Bleeding disorders or anticoagulation: increased bleeding risk due to antiplatelet effect
Monitoring: Check renal function and electrolytes in at-risk patients. Monitor blood pressure. Consider GI prophylaxis with proton pump inhibitors in high-risk patients.
Drug interactions
Pharmacodynamic interactions
- Anticoagulants (warfarin, heparin, DOACs): increased bleeding risk due to additive antiplatelet effect and potential GI ulceration; monitor closely
- Antiplatelet agents (aspirin, clopidogrel): increased bleeding risk; low-dose aspirin for cardioprotection may be continued but increases GI risk
- SSRIs/SNRIs: increased risk of GI bleeding through serotonin effects on platelet function
- Corticosteroids: additive GI ulceration risk
- Other NSAIDs including aspirin: increased adverse effects without additional benefit; avoid concurrent use
Effects on other drugs
- ACE inhibitors and ARBs: naproxen reduces antihypertensive efficacy and increases risk of renal impairment, especially with volume depletion or pre-existing renal disease
- Diuretics: reduced diuretic efficacy; increased risk of renal impairment and hyperkalemia (especially with potassium-sparing diuretics)
- Beta-blockers: may reduce antihypertensive effect
- Lithium: naproxen reduces renal lithium clearance, increasing lithium levels and toxicity risk; monitor lithium concentrations
- Methotrexate: NSAIDs reduce renal methotrexate clearance, increasing toxicity risk, particularly at high methotrexate doses
- Cyclosporine and tacrolimus: increased nephrotoxicity risk
Pharmacokinetic interactions
- CYP2C9 inhibitors (fluconazole, amiodarone): may increase naproxen concentrations
- Probenecid: decreases naproxen clearance, increasing plasma concentrations
- Cholestyramine: may reduce naproxen absorption
Clinical approach: Review medication list before prescribing naproxen. Consider GI prophylaxis in patients on anticoagulants or SSRIs. Monitor renal function in patients on ACE inhibitors, ARBs, or diuretics. Adjust doses of interacting drugs as needed.
Clinical pearls
- Longer half-life advantage: Naproxen's 12-17 hour half-life allows twice-daily dosing (compared to ibuprofen's 6-8 hour dosing interval)
- Cardiovascular risk profile: Among non-selective NSAIDs, naproxen may have the lowest cardiovascular risk due to sustained antiplatelet effects
- GI protection strategy: Co-prescribe a proton pump inhibitor for patients with GI risk factors (age >65, prior ulcer history, concurrent anticoagulant or antiplatelet use)
- Renal-aware dosing: Avoid in severe renal impairment (CrCl <30 mL/min). In volume-depleted states (dehydration, heart failure, cirrhosis), NSAIDs can precipitate acute kidney injury
- Acute gout: Naproxen is as effective as indomethacin for acute gout but better tolerated. Start promptly at onset of flare for best efficacy
- Dysmenorrhea timing: Most effective when started 1-2 days before expected menses and continued through the first few days
- Aspirin interaction: Naproxen can interfere with the irreversible antiplatelet effect of low-dose aspirin if taken before aspirin. Advise patients to take aspirin at least 2 hours before or 8 hours after naproxen
- OTC vs prescription: Over-the-counter naproxen sodium (220 mg) is equivalent to 200 mg naproxen base. Prescription strengths allow higher dosing for inflammatory conditions
- Hepatotoxicity monitoring: Check baseline liver enzymes in patients with liver disease or on hepatotoxic drugs. Discontinue if transaminases exceed 3 times upper limit of normal
- Exam tip: Questions often contrast naproxen's longer half-life with ibuprofen's shorter half-life, or test recognition of NSAID complications in high-risk patients
Practice questions
1. A 68-year-old man with a history of coronary artery disease and a recent drug-eluting stent is taking aspirin 81 mg daily and clopidogrel. He develops acute gouty arthritis of his right first metatarsophalangeal joint. His physician prescribes naproxen 500 mg twice daily. Three days later, he presents to the emergency department with melena and hematemesis. His hemoglobin is 7.2 g/dL (baseline 14 g/dL). Upper endoscopy reveals multiple gastric ulcers with active bleeding. What is the most significant contributor to this patient's presentation?
2. A 72-year-old woman with osteoarthritis, hypertension, and chronic kidney disease (baseline creatinine 1.8 mg/dL) presents with acute-onset oliguria and lower extremity edema. She recently started taking over-the-counter naproxen 440 mg twice daily for worsening knee pain. Her current medications include lisinopril, hydrochlorothiazide, and amlodipine. Laboratory studies show creatinine 3.2 mg/dL, BUN 54 mg/dL, and potassium 5.8 mEq/L. Urinalysis shows no protein, blood, or casts. Which mechanism best explains her acute kidney injury?
3. A 28-year-old woman with a history of asthma and nasal polyps presents to the emergency department with acute dyspnea, wheezing, and facial angioedema 30 minutes after taking naproxen for menstrual cramps. Her oxygen saturation is 88% on room air. She reports a similar reaction to aspirin two years ago. Which mechanism best explains her presentation?
Frequently asked questions
How does naproxen work?
Naproxen works by reversibly inhibiting both COX-1 and COX-2 enzymes, which prevents the conversion of arachidonic acid to prostaglandins. Prostaglandins mediate inflammation, pain, and fever, so blocking their synthesis provides therapeutic relief. COX-1 inhibition also reduces protective gastric prostaglandins (causing GI side effects) and affects platelet function (antiplatelet effect). The drug's non-selective mechanism distinguishes it from COX-2 selective inhibitors like celecoxib.
What are the side effects of naproxen?
The most common side effects include dyspepsia, nausea, and abdominal pain. Serious adverse effects include gastrointestinal bleeding and ulceration, cardiovascular events (heart attack, stroke), acute kidney injury, and fluid retention. Naproxen can also cause elevated blood pressure, liver enzyme elevations, and increased bleeding risk. Hypersensitivity reactions including bronchospasm can occur in aspirin-sensitive individuals. Elderly patients face higher risks of serious GI and cardiovascular complications.
Is naproxen a controlled substance?
No, naproxen is not a controlled substance. It is a non-steroidal anti-inflammatory drug (NSAID) available both over-the-counter at lower strengths (typically 220 mg naproxen sodium) and by prescription at higher strengths. It has no abuse potential or dependence risk. However, it does require careful use due to cardiovascular and gastrointestinal risks, particularly with long-term use or in high-risk populations.
Can I take naproxen with ibuprofen?
No, you should not take naproxen and ibuprofen together. Both are non-selective NSAIDs that inhibit the same COX enzymes, so combining them increases the risk of adverse effects (especially GI bleeding, kidney injury, and cardiovascular events) without providing additional therapeutic benefit. If one NSAID is insufficient for pain control, discuss alternatives with a healthcare provider rather than adding a second NSAID. The exception is low-dose aspirin for cardiovascular protection, which may be continued with careful timing.
Naproxen vs ibuprofen — what is the difference?
The main difference is half-life: naproxen has a half-life of 12-17 hours allowing twice-daily dosing, while ibuprofen's 2-4 hour half-life requires dosing every 6-8 hours. Both are non-selective NSAIDs with similar mechanisms and efficacy for pain and inflammation. Naproxen may have a slightly lower cardiovascular risk profile than ibuprofen. Both carry similar GI and renal risks. The choice often depends on dosing convenience, with naproxen preferred for chronic conditions requiring less frequent dosing.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: G02CC02WHO ATC/DDD index: M01AE02
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.